Still Hungry for New Obesity Drugs, Novo Nordisk Finalizes Another M&A Deal – MedCity News
Novo Nordisk is already an obesity drug giant with its blockbuster Wegovy, but its appetite for cardiometabolic drugs continues. The Danish pharmaceutical giant is satisfying that hunger by acquiring a startup with a new approach to weight loss, sealing its second acquisition deal this month. The latest acquisition target is Embark Biotech. Under the terms …